Page last updated: 2024-09-02

idarubicinol and docetaxel anhydrous

idarubicinol has been researched along with docetaxel anhydrous in 1 studies

Compound Research Comparison

Studies
(idarubicinol)
Trials
(idarubicinol)
Recent Studies (post-2010)
(idarubicinol)
Studies
(docetaxel anhydrous)
Trials
(docetaxel anhydrous)
Recent Studies (post-2010) (docetaxel anhydrous)
5410012,1103,2166,920

Protein Interaction Comparison

ProteinTaxonomyidarubicinol (IC50)docetaxel anhydrous (IC50)
Kinesin-like protein KIF11Homo sapiens (human)0.0014
Nucleotide-binding oligomerization domain-containing protein 2Homo sapiens (human)5.0119

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aita, P; Bearz, A; Boiocchi, M; Colussi, AM; Corona, G; Crivellari, D; Robieux, I; Sorio, R; Stocco, F; Toffoli, G1

Trials

1 trial(s) available for idarubicinol and docetaxel anhydrous

ArticleYear
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:6

    Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Cyclophosphamide; Daunorubicin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Idarubicin; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors

2000